CD38
52 programs · 49 companies
Programs
52
Companies
49
Active Trials
37
Targeting CD38
| Drug | Company | Phase | MOA | Indications |
|---|---|---|---|---|
| Terafutibatinib | Pfizer | Phase 1/2 | CeliacGastric Ca | |
| Tirafotisoran | Roche | Phase 2 | AngelmanPNH | |
| NVS-6360 | Novartis | Approved | FTD | |
| Doxasotorasib | AbbVie | Phase 2 | MSSMA | |
| SNY-2289 | Sanofi | Phase 2/3 | Wilms | |
| NVO-1361 | Novo Nordisk | Phase 3 | GBMUrothelial Ca | |
| AMG-2597 | Amgen | Phase 2/3 | CFCSU | |
| Ivosotorasib | Vertex Pharma | Preclinical | RSVEwing Sarcoma | |
| Zenotapinarof | Vertex Pharma | Preclinical | Cholangiocarcinoma | |
| Motazanubrutinib | Biogen | Preclinical | WilmsLN | |
| BMR-8526 | BioMarin | Phase 1/2 | AS | |
| Zanufutibatinib | Intra-Cellular | NDA/BLA | FabryRB | |
| Bemasotorasib | Exelixis | Phase 2 | MCLACC | |
| Bemanaritide | Blueprint Medicines | Phase 2 | Dravet | |
| RCK-1666 | Rocket Pharma | Approved | CSUDMD | |
| RDY-8710 | Dr Reddy's | Approved | ADHDCervical Ca | |
| Nidaglumide | Akeso | Preclinical | MG | |
| NIA-IIT-407 | NIAID | Phase 2 | FSGS | |
| UCL-IIT-586 | UCLA Health | Phase 3 | Breast Ca | |
| QUO-6518 | Quotient Ther | Preclinical | ETGIST | |
| Voxazumab | Asklepios Bio | Phase 1 | SCD | |
| ATL-9462 | Atlas Venture | Phase 2/3 | FLPNH | |
| Pexasertib | Atlas Venture | Preclinical | NBFSGS | |
| Nidasertib | Crinetics Pharma | Approved | OCDUrothelial Ca | |
| DMA-2916 | DiaMedica Therapeutics | Phase 1/2 | ADPKDHeart Failure | |
| Voxasotorasib | Corvus Pharma | Phase 3 | Ewing SarcomaAS | |
| Nidazumab | China Biologic | Phase 1 | PSPPsA | |
| Gozerapivir | Adlai Nortye | Phase 2 | EoETTR Amyloidosis | |
| Ivofotisoran | Sierra Oncology (GSK) | NDA/BLA | EpilepsyCrohn's | |
| Mirivorutinib | Celgene (BMS) | Phase 3 | RSVEoE | |
| 300-2164 | Betta Pharma | Phase 3 | MCL | |
| Ivovorutinib | Eutilex | NDA/BLA | MCC | |
| Kemafutibatinib | Orbital Ther | Phase 3 | DLBCL | |
| Niratenlimab | Bridgebio | Phase 1 | SCLC | |
| CAR-9866 | Cara Ther | Phase 3 | CTCLWilms | |
| AVA-8598 | Avanir (Otsuka) | Phase 2/3 | CeliacParkinson's | |
| ASK-1666 | Askbio (Bayer) | Approved | Melanoma | |
| 006-348 | GC Pharma | Phase 1/2 | FabryProstate Ca | |
| Daracilimab | Zydus Life | Phase 2 | Prostate CaNASH | |
| STA-6655 | Strides Pharma | NDA/BLA | FTD | |
| Riboinavolisib | Windlas Bio | Phase 2 | MDD | |
| IMV-3466 | Immunovant | Phase 1 | FLSCLC | |
| Taladerotide | BTG (Boston Sci) | Phase 1 | ObesityCF | |
| BEL-9345 | Bellus Health (GSK) | NDA/BLA | WilmsNSCLC | |
| Elranaritide | Jamjoom Pharma | NDA/BLA | IPF | |
| ABD-5382 | Abdi Ibrahim | Preclinical | Prostate CaACC | |
| Lisotapinarof | Abdi Ibrahim | NDA/BLA | CFNMOSD | |
| AMO-1639 | Amoun Pharma | Phase 2 | Wet AMDMDS | |
| HOS-IIT-414 | Hospital Israelita Einstein | NDA/BLA | DMD | |
| Liramavacamten | West Pharma | Phase 1 | FSGSEwing Sarcoma | |
| BLC-3714 | Bausch + Lomb | Approved | RSVSCD | |
| Gelirasimod | Medicago (PMI) | NDA/BLA | BCCMelanoma |